A comprehensive analysis of SLC25A1 expression and its oncogenic role in pan-cancer

被引:0
作者
Xin You
Lingling Huang
Ouxiang Huang
Yujie Deng
Xi Shi
机构
[1] The First Affiliated Hospital of Fujian Medical University,Department of Oncology
[2] The First Affiliated Hospital of Fujian Medical University,Molecular Oncology Research Institute
[3] Fujian Medical University,Department of Oncology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital
来源
Discover Oncology | / 14卷
关键词
SLC25A1; Pan-cancer; Prognosis; Tumor immunity; Therapeutic target;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 81 条
[1]  
Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249
[2]  
Liu J(2021)Therapeutic advances in oncology Int J Mol Sci 21 141-162
[3]  
Pandya P(2022)Targeting cancer metabolism in the era of precision oncology Nat Rev Drug Discov 38 27-1235
[4]  
Afshar S(2018)Lipid metabolism reprogramming and its potential targets in cancer Cancer Commun 20 28-1258
[5]  
Stine Z(2021)The cancer metabolic reprogramming and immune response Mol Cancer 161 105132-1225
[6]  
Cheng C(2020)Advances into understanding the vital role of the mitochondrial citrate carrier (CIC) in metabolic diseases Pharmacol Res 3 1220-258
[7]  
Xia L(2021)The mitochondrial citrate carrier SLC25A1/CIC and the fundamental role of citrate in cancer, inflammation and beyond Biomolecules 25 1239-244
[8]  
Peng R(2021)Understanding the central role of citrate in the metabolism of cancer cells and tumors: an update Int J Mol Sci 12 1108-416
[9]  
Mosaoa R(2020)Mitochondrial SLC25 carriers: novel targets for cancer therapy Molecules 8 170-660
[10]  
Icard P(2012)The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis Oncotarget 5 1212-27